CDT Equity Inc. (CDT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

CDT Equity Inc. (CDT) closed at USD 0.24 on 2026-10-14, a change of -100 % over the past year, with a market capitalization of USD 235,023.

CDT Equity Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

CDT Equity Inc. key figures

Previous close

USD 0.24 (2026-10-14)

1-year change

-100 %

Market cap

USD 235,023

Enterprise value

USD 441,576

P/E ratio (trailing)

0.00

P/E ratio (forward)

n/a

EPS (trailing)

46,679.71

EPS (forward)

n/a

PEG ratio

n/a

Price to book

0.00

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.10

Employees

4

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About CDT Equity Inc.

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for CDT Equity Inc. and compare it with other stocks.